Dolutegravir in contributing the 90:90:90 ambition

47 Pages·2016·3.68 MB·English

Dolutegravir in contributing
the 90:90:90 ambition
Tuna LUKIANA MD, PhD
Head, Medical Affairs Middle East & Africa
ViiV Healthcare
Yaoundé, 04th May 20161
DISCLOSURE
• Employee of ViiV Healthcare working with
GlaxoSmithKline
2
UNAIDS 90-90-90 target for 2020 to end AIDS by 2030
3
3
Fund
90:90:90: The Spectrum
Research
PMTCT
Others….
High risk
Population
Testing
Supply Chain
ARV
Human
rights
Healthcare
Goverments
Care
and Policies
Capacities
Management
and
of co
capabilities
Community
morbidities
Social
conditions s
Children
Prevention
4
90:90:90: The Spectrum
ARV
5
2016: ARV HISTORY
Genvoya, TAF ?
Dolutegravir, Elvitegravir
ARV Classes
Rilpivirine
NRTIs Etravirine
NNRTIs Maraviroc, raltegravir, darunavir
PIs Tipranavir
Fusion inhibitor Enfuvirtide, fosamprenavir, atazanavir
CCR5 inhibitor Emtricitabine
Integrase inhibitor Tenofovir
Lopinavir/r
Efavirenz, abacavir, amprenavir
Nevirapine, nelfinavir
Delavirdine
Stavudine, Lamivudine, saquinavir, ritonavir, indinavir
Zidovudine
AIDS,
Zalcitabine
LAV
1st case
(HIV) Didanosine
e
1 3 7 1 2 6 7 8 9 1 2 3 4 5 7 8 23 ru
8 8 8 9 9 9 9 9 9 0 0 0 0 0 0 0 11 t
9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 00 u
1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 22 F
1981 1990 2000 2010
6
Confidential and proprietary –internal use only Job code: VIIV/DGR/0007/15 Date of preparation: June 2015
2003–2010: CORE AGENTS DRIVE ADVANCEMENTS IN
HIV THERAPY
Meta-analysis shows that from 1995 to 2010 the overall mean efficacy of initial
therapy for HIV-1 improved
7
Lee FJ et al. PLoS One 2014;9:e97482
HIV: FIGHT IS NOT OVER…
8
UNAIDS 90-90-90 target for 2020 to end AIDS by 2030
9
9
ARVs: REACH & MAINTAIN UNDETECTABILITY ?
Efficacy
10